
At a glance:
Research in mice shows that inflammatory molecules influence mood and behavior by acting on specific brain regions.
The findings help explain why some people experience lasting mood changes after infections or autoimmune disease flare-ups.
The research could lead to new therapies for anxiety disorders and autism spectrum disorders.
Physicians have long observed a mystifying phenomenon: After a bout of infection or an autoimmune disease flare-up, some people experience prolonged mood swings, emotional dysregulation, and changes in behavior. But the precise connection between inflammation, mood, and behavior has remained elusive.
Now, two new studies from Harvard Medical School and Massachusetts Institute of Technology, published April 7 in Cell, detail the steps of an intricate brain-immune crosstalk that accounts for this long-known but poorly understood observation.
The work, conducted in mice and funded in part by the National Institutes of Health, pinpoints the molecular roots of the phenomenon and shows how immune molecules called cytokines influence brain activity.
Scientists already knew that cytokines affect emotions and brain function, but how and where in the brain this occurs has thus far remained unclear. The new research maps a network of cytokine signals that interact with specific brain cells to regulate mood, anxiety, and social behavior.
If confirmed in further studies in animals and people, these findings could lead to new therapies for autism and anxiety disorders. These treatments would work indirectly by altering immune chemicals to calm the immune system rather than by acting directly on the brain like traditional psychiatric drugs do. Those drugs must cross the protective blood-brain barrier to change brain chemistry directly, while the new approaches could work by adjusting immune signals from outside the brain.
Authorship, funding, disclosures
Additional authors on the two studies included Byeongjun Lee, Jeong-Tae Kwon, Yire Jeong, Hannah Caris, Dongsun Oh, Mengyang Feng, Irene Davila Mejia, Xiaoying Zhang, Tomoe Ishikawa, Brianna R. Watson, Jeffrey R. Moffitt, Kwanghun Chung, Yunjin Lee, Hyeseung Lee, Changhyeon Ryu, Minjin Kim, Guangqing Lu, Yujin Hong, Hyeyoon Shin, Sylvain Meloche, Richard M. Locksley, Ekaterina Koltsova, Sergei I. Grivennikov, and Myriam Heiman.
The two studies were supported by NIH grants 5P30EY012196, R01-MH115037, R01-MH119459, R01-CA227629, and R01-CA218133; the Jeongho Kim and the Brain Impact Foundation Neuro-Immune Fund; Young Soo Perry and Karen Ha; the Simons Center for the Social Brain; the Simons Foundation Autism Research Initiative; The Marcus Foundation; N of One: Autism Research Foundation; the Burroughs Wellcome Fund; a Simons Center for the Social Brain Postdoctoral Fellowship; a JSPS Overseas Research Fellowship; a Yamada Science Foundation Overseas Research Fellowship; a Harvard Brain Science Initiative Postdoc Pioneers Grant; Barbara Picower; the Freedom Together Foundation; The Picower Institute for Learning and Memory; and the MIT John W. Jarve (1978) Seed Fund for Science Innovation.
Huh and Choi consult for CJ CheilJedang and Interon Laboratories. Huh is an advisor on the Samsung Bio Advisory Board.